Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Collaborators
NCT07081022 · B-cell Non-Hodgkin's Lymphoma
NCT04533581 · Indolent B-cell Non-Hodgkin's Lymphoma
NCT07334574 · B-cell Non-Hodgkin's Lymphoma (B-NHL)
NCT03985189 · Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
NCT05190068 · B-Cell Non-Hodgkin's Lymphoma
The Christ Hospital
Cincinnati, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions